Centre for Nephrology, University College London, London, UK.
Department of Medicine, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
Kidney Int. 2016 Jun;89(6):1189-91. doi: 10.1016/j.kint.2016.02.045.
The clinical benefits of statins in dialysis patients are unproven. New follow-up data from the 4D Study indicate no clear reduction in cardiovascular events among patients with type-2 diabetes. Assessing outcomes 7.4 years beyond the randomization period (20 mg atorvastatin versus placebo), no differences in a composite cardiovascular outcome were observed and no safety concerns emerged. Current Kidney Disease: Improving Global Outcomes (KDIGO) guidelines do not need updating based on these new data.
他汀类药物在透析患者中的临床获益尚未得到证实。来自 4D 研究的新随访数据表明，2 型糖尿病患者的心血管事件并未明显减少。在随机分组后 7.4 年评估结果（阿托伐他汀 20mg 与安慰剂），复合心血管结局无差异，也未出现安全性问题。根据这些新数据，目前的肾脏病：改善全球预后（KDIGO）指南无需更新。
